These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35068214)

  • 1.
    Upchurch WJ; Iaizzo PA
    Exp Biol Med (Maywood); 2022 Apr; 247(7):584-597. PubMed ID: 35068214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro contracture testing for determination of susceptibility to malignant hyperthermia: a methodologic update.
    Iaizzo PA; Wedel DJ; Gallagher WJ
    Mayo Clin Proc; 1991 Oct; 66(10):998-1004. PubMed ID: 1833602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of halothane equilibration kinetics on in vitro muscle contractures for malignant hyperthermia screening.
    Urwyler A; Funk B; Censier K; Drewe J
    Acta Anaesthesiol Scand; 1992 Feb; 36(2):115-8. PubMed ID: 1549929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].
    Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD
    Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
    Ginz HF; Girard T; Censier K; Urwyler A
    Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
    Larach MG; Landis JR; Bunn JS; Diaz M
    Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halothane-caffeine contracture testing in neuromuscular diseases.
    Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
    Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
    Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H
    Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.
    Larach MG
    Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676
    [No Abstract]   [Full Text] [Related]  

  • 12. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
    Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
    Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant hyperthermia in humans--standardization of contracture testing protocol.
    Melton AT; Martucci RW; Kien ND; Gronert GA
    Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility.
    Ording H; Islander G; Bendixen D; Ranklev-Twetman E
    Anesth Analg; 2000 Aug; 91(2):452-7. PubMed ID: 10910867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does prior dantrolene affect the in vitro diagnosis of malignant hyperthermia susceptibility?
    Nelson TE; Flewellen EH
    Can Anaesth Soc J; 1979 Nov; 26(6):484-8. PubMed ID: 526874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro determination of susceptibility to malignant hyperthermia.
    Iaizzo PA; Lehmann-Horn F
    Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contracture test with ionophore A 23187 for the diagnosis of malignant hyperthermia].
    Moeller R; Kozak-Reiss G; Gascard JP; Laxenaire MC
    Ann Fr Anesth Reanim; 1986; 5(2):177-81. PubMed ID: 3089080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia.
    Hoppe K; Schleip R; Lehmann-Horn F; Jäger H; Klingler W
    Anaesthesia; 2014 Sep; 69(9):1002-8. PubMed ID: 24909539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.